Evidence map›Paper›PMID 42461516›Full record

ArticleInternational journal of clinical oncology2026

Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study.

Shigeki Koterazawa, Takayuki Sumiyoshi, Noboru Shibasaki, Toshinari Yamasaki, Noriyuki Ito, Takehiko Segawa, Koji Inoue, Sojun Kanamaru, Toru Yoshida, Kazutoshi Okubo and 15 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Shigeki KoterazawaDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Takayuki SumiyoshiDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Noboru ShibasakiDepartment of Urology, Kobe City Medical Center General Hospital, Hyogo, Japan.
Toshinari YamasakiDepartment of Urology, Kobe City Medical Center General Hospital, Hyogo, Japan.
Noriyuki ItoDepartment of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Takehiko SegawaDepartment of Urology, Kyoto City Hospital, Kyoto, Japan.
Koji InoueDepartment of Urology, Kurashiki Central Hospital, Okayama, Japan.
Sojun KanamaruDepartment of Urology, Kobe City Nishi-Kobe Medical Center, Hyogo, Japan.
Toru YoshidaDepartment of Urology, Shiga General Hospital, Shiga, Japan.
Kazutoshi OkuboDepartment of Urology, Kyoto-Katsura Hospital, Kyoto, Japan.
Yoshio SuginoDepartment of Urology, National Hospital Organization Himeji Medical Center, Hyogo, Japan.
Toru KannoDepartment of Urology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Norihiko MasudaDepartment of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan.
Masakatsu UedaDepartment of Urology, Shizuoka General Hospital, Shizuoka, Japan.
Shuhei KoikeDepartment of Urology, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.
Akihiro HoshiyamaDepartment of Urology, Japanese Red Cross Otsu Hospital, Shiga, Japan.
Hiromasa ArakiDepartment of Urology, Hamamatsu Rosai Hospital, Shizuoka, Japan.
Ken MaekawaDepartment of Urology, Osaka Red Cross Hospital, Osaka, Japan.
Takaaki TakumaDepartment of Urology, Toyooka Hospital, Hyogo, Japan.
Takehiro YamaneDepartment of Urology, Tenri Hospital, Nara, Japan.
Yuki KitaDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Takayuki GotoDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Takashi Kobayashi *Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Kimihiko Masui *Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. kimimasu1389@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-7841-1104
Daimonji Clinical Application Database Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigher body mass index (BMI) has been associated with favorable prognosis in renal cell carcinoma (RCC), a phenomenon known as the "obesity paradox". However, this relationship may differ by sex. Moreover, previous studies have insufficiently accounted for laboratory-based nutritional status and mainly focused on low-risk populations. Consequently, the prognostic value of BMI in patients with high-risk localized RCC remains unclear.

methodsWe conducted a retrospective multicenter study of patients with high-risk localized RCC who underwent curative surgery between 2010 and 2022. Patients were stratified by BMI (≥ 25 vs. < 25 kg/m

resultsA total of 668 patients were included, of which 243 developed disease recurrence during follow-up. In the overall cohort, BMI ≥ 25 kg/m

conclusionHigher BMI was independently associated with more favorable oncological outcomes in patients with high-risk localized RCC, particularly in males. BMI may therefore have sex-specific prognostic value in this population.

Indexed as

Body Mass IndexCarcinoma, Renal CellKidney NeoplasmsNephrectomyAgedDisease-Free SurvivalFemaleHumansMaleMiddle AgedObesityPrognosisRetrospective StudiesSex FactorsBody mass indexDisease-free survivalHigh-risk diseaseNutritional statusRenal cell carcinomaSex differences

Identifiers

PMID42461516

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.